A Complete Account of EMA Approvals in 2023

Shots: In 2023, EMA approved around 45 drugs in various therapy areas, ranging from cardiology, oncology, hematology, neurology, and dermatology to infectious diseases, genetics, pulmonary, otolaryngology, gastroenterology, ophthalmology, and endocrinology PharmaShots, in an illuminating report, brings a condensed analysis of the approved drugs with the most explored areas being Oncology, Hematology, Neurology, & Dermatology For…

BySenior EditorMarch 5, 2024

INSIGHTS+

A Complete Account of FDA Approvals in 2023

Shots: 2023 remained a year of notable approvals by the US FDA. Around 55 drugs were approved, by the US FDA in 2023 PharmaShots, in an enlightening report, brings a summarized analysis of the approved drugs. The most explored section remains Oncology, Neurology, and Hematology  For the complete report with analysis, reach out to us…

BySenior EditorFebruary 1, 2024

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2023

Shots: The Fourth quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. Starting with the latest acquisitions, BMS acquired Mirati Therapeutics for ~$5.8B and AbbVie acquired ImmunoGen for $10.1B The Fourth quarter of the year also showcases multiple clinical trial results from Regeneron’s Two-Year…

BySenior EditorJanuary 16, 2024

INSIGHTS+

Top Performing Drug – Xtandi (December Edition)

Shots: In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Xtandi and prepared a curated analysis report for our readers Xtandi is indicated for the treatment of certain prostate cancers PharmaShots presents a concise take on the key features of Xtandi with…

BySenior EditorDecember 28, 2023

INSIGHTS+

Top Performing Drug – Cosentyx (November Edition)

Shots: In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Cosentyx and prepared a curated analysis report for our readers Cosentyx is indicated for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It is a human IgG1κ mAb which targets interleukin (IL)-17A PharmaShots presents a…

BySenior EditorNovember 22, 2023

INSIGHTS+

Top Performing Drug – Tagrisso (October Edition)

Shots: In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Tagrisso and prepared a curated analysis report for our readers Tagrisso is indicated for the treatment of non-small-cell lung carcinomas with specific mutations. It is a 3rd generation drug that belongs to the…

BySenior EditorOctober 25, 2023

INSIGHTS+

Top Performing Drug – Ocrevus (July Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, we bring for our readers a concise yet thorough analysis of the drug Ocrevus Ocrevus is a prescription medicine used to treat adults with relapsing or primary progressive multiple sclerosis including CIS, RRMS, and SPMS PharmaShots presents…

BySenior EditorJuly 26, 2023

INSIGHTS+

Top Performing Drug – Enbrel (June Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Enbrel as the top-performing drug of the month Enbrel is a biologic drug classified as a TNF inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other autoimmune diseases PharmaShots…

BySenior EditorJune 28, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in February 2023

Shots: The US FDA approved 5 NDAs and 5 BLA in February 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 19 novel products in 2023 In February 2023, the major highlights drugs were, Tezspire (tezepelumab) approval for severe asthma, Altuviiio for hemophilia A PharmaShots has compiled…

BySenior EditorMarch 15, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in January 2022

The US FDA has approved 3 NDAs and 2 BLAs in Jan 2022, leading to treatments for patients and advances in the health care industry. The CDER and CBER approved 5 novel products in 2022 In Jan 2022, the major highlights were Quviviq's approval for insomnia, Cibinqo for atopic dermatitis, Kimmtrak for unresectable or metastatic…

BySenior EditorFebruary 17, 2022

A Complete Account of EMA Approvals in 2023

A Complete Account of FDA Approvals in 2023

PharmaShots’ Key Highlights of Fourth Quarter 2023

Top Performing Drug – Xtandi (December Edition)

Top Performing Drug – Cosentyx (November Edition)

Top Performing Drug – Tagrisso (October Edition)

Top Performing Drug – Ocrevus (July Edition)

Top Performing Drug – Enbrel (June Edition)

Insights+: The US FDA New Drug Approvals in February 2023

Insights+: The US FDA New Drug Approvals in January 2022

Contact US

FOLLOW US